Our Research

Literature Cited

  1. Bloom WL, McGhee WJ, Cromartie WJ, Watson DW (1947) Studies on infection with Bacillus anthracis.  VI. Physiological changes in experimental animals during the course of infection with b. anthracis. J Infect Dis 80: 137–144.
  2. Smith H, Keppie J (1954) Observations on experimental anthrax: demonstration of a specific lethal factor produced in vivo by Bacillus anthracis. Nature 173: 869–870.
  3. Keppie J, Smith H, Harris-Smith PW (1953) The chemical basis of the virulence of Bacillus anthracis.  II: Some biological properties of bacterial products. Brit J Exp Path 34: 486–496.
  4. Cromartie WJ, Watson DW, Bloom WL, Heckly RJ (1947) Studies on infection with Bacillus anthracis.  II. The immunological and tissue damaging properties of extracts prepared from lesions of B. anthracis infection. J Infect Dis 80: 14–27.
  5. Smith H, Tempest DW, Stanley JL, Harris-Smith PW, Gallop RC (1956) The chemical basis of the virulence of Bacillus anthracis.  VII. Two components of the anthrax toxin: their relationship to known immunising aggressins. Brit J Exp Path 37: 263–271.
  6. Stanley JL, Smith H (1961) Purification of factor I and recognition of a third factor of the anthrax toxin. J Gen Microbiol 26: 49–66.
  7. Beall FA, Taylor MJ, Thorne CB (1962) Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J Bacteriol 83: 1274–1280.
  8. Fish DC, Lincoln RE (1968) In vivo-produced anthrax toxin. J Bacteriol 95: 919–924.
  9. Friedlander AM (1986) Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem 261: 7123–7126.
  10. Mikesell P, Ivins BE, Ristroph JD, Dreier TM (1983) Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immun 39: 371–376.
  11. Vodkin MH, Leppla SH (1983) Cloning of the protective antigen gene of Bacillus anthracis. Cell 34: 693–697.
  12. Welkos SL, Lowe JR, Eden-McCutchan F, Vodkin M, Leppla SH, et al. (1988) Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis. Gene 69: 287–300.
  13. Petosa C, Collier RJ, Klimpel KR, Leppla SH, Liddington RC (1997) Crystal structure of the anthrax toxin protective antigen. Nature 385: 833–838.
  14. Klimpel KR, Molloy SS, Thomas G, Leppla SH (1992) Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A 89: 10277–10281.
  15. Leppla SH (1991) The anthrax toxin complex. In: Freer Aa, editor. Sourcebook of Bacterial Protein Toxins. London: Academic Press. pp. 277–302.
  16. Benson EL, Huynh PD, Finkelstein A, Collier RJ (1998) Identification of residues lining the anthrax protective antigen channel. Biochemistry 37: 3941–3948.
  17. Batra S, Gupta P, Chauhan V, Singh A, Bhatnagar R (2001) Trp 346 and Leu 352 residues in protective antigen are required for the expression of anthrax lethal toxin activity. Biochem Biophys Res Commun 281: 186–192.
  18. Novak JM, Stein M-P, Little SF, Leppla SH, Friedlander AM (1992) Functional characterization of protease-treated Bacillus anthracis protective antigen. J Bio Chem 267: 17186–17193.
  19. Singh Y, Klimpel KR, Arora N, Sharma M, Leppla SH (1994) The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor. J Biol Chem 269: 29039–29046.
  20. Khanna H, Chopra AP, Arora N, Chaudhry A, Singh Y (2001) Role of residues constituting the 2beta1 strand of domain II in the biological activity of anthrax protective antigen. FEMS Microbiol Lett 199: 27–31.
  21. Sellman BR, Nassi S, Collier RJ (2001) Point mutations in anthrax protective antigen that block translocation. J Biol Chem 276: 8371–8376.
  22. Mogridge J, Mourez M, Collier RJ (2001) Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. J Bacteriol 183: 2111–2116.
  23. Khanna H, Gupta PK, Singh A, Chandra R, Singh Y (2001) Participation of residue F552 in domain III of the protective antigen in the biological activity of anthrax lethal toxin. Biol Chem 382: 941–946.
  24. Ahuja N, Kumar P, Bhatnagar R (2001) Hydrophobic residues Phe552, Phe554, Ile562, Leu566, and Ile574 are required for oligomerization of anthrax protective antigen. Biochem Biophys Res Commun 287: 542–549.
  25. Little SF, Leppla SH, Cora E (1988) Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 56: 1807–1813.
  26. Singh Y, Klimpel KR, Quinn CP, Chaudhary VK, Leppla SH (1991) The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J Bio Chem 266: 15493–15497.
  27. Noskov AN, Kravchenko TB, Noskova VP (1996) [Detection of the functionally active domains in the molecule of the lethal factor of the anthrax exotoxin]. Mol Gen Mikrobiol Virusol 3: 20–22.
  28. Varughese M, Teixeira AV, Liu S, Leppla SH (1999) Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect Immun 67: 1860–1865.
  29. Brossier F, Sirard JC, Guidi-Rontani C, Duflot E, Mock M (1999) Functional analysis of the carboxy-terminal domain of Bacillus anthracis protective antigen. Infect Immun 67: 964–967.
  30. Rosovitz MJ, Schuck P, Varughese M, Chopra AP, Mehra V, et al. (2003) Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J Biol Chem 278: 30936–30944.
  31. Mock M, Labruyere E, Glaser P, Danchin A, Ullmann A (1988) Cloning and expression of the calmodulin-sensitive Bacillus anthracis adenylate cyclase in Escherichia coli. Gene 64: 277–284.
  32. Tippetts MT, Robertson DL (1988) Molecular cloning and expression of the Bacillus anthracis edema factor toxin gene: a calmodulin-dependent adenylate cyclase. J Bacteriol 170: 2263–2266.
  33. Robertson DL, Tippetts MT, Leppla SH (1988) Nucleotide sequence of the Bacillus anthracis edema factor gene (cya): a calmodulin-dependent adenylate cyclase. Gene 73: 363–371.
  34. Leppla SH (1982) Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A 79: 3162–3166.
  35. Craig JP (1965) A permeability factor (toxin) found in cholera stools and culture filtrates and its neutralization by convalescent cholera sera. Nature 207: 614–616.
  36. Johnson GS, Friedman RM, Pastan I (1971) Restoration of several morphological characteristics of normal fibroblasts in sarcoma cells treated with adenosine-3':5'-cyclic monophosphate and its derivatives. Proc Natl Acad Sci USA 68: 425–429.
  37. Leppla SH (1984) Bacillus anthracis calmodulin-dependent  adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. In: Greengard P, editor. Advances in Cyclic Nucleotide and Protein Phosphorylation Research. New York: Raven Press. pp. 189–198.
  38. Drum CL, Yan SZ, Bard J, Shen YQ, Lu D, et al. (2002) Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature 415: 396–402.
  39. Robertson DL, Leppla SH (1986) Molecular cloning and expression in Escherichia coli of the lethal factor gene of Bacillus anthracis. Gene 44: 71–78.
  40. Bragg TS, Robertson DL (1989) Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracis. Gene 81: 45–54.
  41. Quinn CP, Singh Y, Klimpel KR, Leppla SH (1991) Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis. J Biol Chem 266: 20124–20130.
  42. Mehra V, Khanna H, Chandra R, Singh Y (2001) Anthrax-toxin-mediated delivery of a 19 kDa antigen of Mycobacterium tuberculosis into the cytosol of mammalian cells. Biotechnol Appl Biochem 33: 71–74.
  43. Arora N, Klimpel KR, Singh Y, Leppla SH (1992) Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J Biol Chem 267: 15542–15548.
  44. Arora N, Leppla SH (1993) Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J Biol Chem 268: 3334–3341.
  45. Arora N, Leppla SH (1994) Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells. Infect Immun 62: 4955–4961.
  46. Sharma M, Khanna H, Arora N, Singh Y (2000) Anthrax toxin-mediated delivery of cholera toxin-A subunit into the cytosol of mammalian cells. Biotechnol Appl Biochem 32 ( Pt 1): 69–72.
  47. Pannifer AD, Wong TY, Schwarzenbacher R, Renatus M, Petosa C, et al. (2001) Crystal structure of the anthrax lethal factor. Nature 414: 229–233.
  48. Molnar DM, Altenbern RA (1963) Alterations in the biological activity of protective antigen of Bacillus anthracis toxin. Soc Exp Biol Med 114: 294–297.
  49. Gill DM (1978) Seven toxin peptides that cross cell membranes. In: Jeljaszewicz J, Wadstrom T, editors. Bacterial toxins and cell membranes. New York: Academic Press. pp. 291–332.
  50. Molloy SS, Bresnahan PA, Leppla SH, Klimpel KR, Thomas G (1992) Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem 267: 16396–16402.
  51. Singh Y, Chaudhary VK, Leppla SH (1989) A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J Biol Chem 264: 19103–19107.
  52. Novak JM, Stein MP, Little SF, Leppla SH, Friedlander AM (1992) Functional characterization of protease-treated Bacillus anthracis protective antigen. J Biol Chem 267: 17186–17193.
  53. Blaustein RO, Koehler TM, Collier RJ, Finkelstein A (1989) Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers. Proc Natl Acad Sci U S A 86: 2209–2213.
  54. Milne JC, Furlong D, Hanna PC, Wall JS, Collier RJ (1994) Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J Biol Chem 269: 20607–20612.
  55. Gordon VM, Leppla SH, Hewlett EL (1988) Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect Immun 56: 1066–1069.
  56. Klimpel KR, Arora N, Leppla SH (1994) Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol Microbiol 13: 1093–1100.
  57. Hammond SE, Hanna PC. Anthrax lethal factor hydrolysis of synthetic peptides.; 1997; Miami Beach, Florida.
  58. Hammond SE, Hanna PC (1998) Lethal factor active-site mutations affect catalytic activity in vitro. Infect Immun 66: 2374–2378.
  59. Vitale G, Pellizzari R, Recchi C, Napolitani G, Mock M, et al. (1998) Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun 248: 706–711.
  60. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, et al. (1998) Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280: 734–737.
  61. Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C (1999) Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett 462: 199–204.
  62. Vitale G, Bernardi L, Napolitani G, Mock M, Montecucco C (2000) Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J 352 Pt 3: 739–745.
  63. Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, et al. (2001) Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci U S A 98: 4089–4094.
  64. Tanoue T, Adachi M, Moriguchi T, Nishida E (2000) A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol 2: 110–116.
  65. Chopra AP, Boone SA, Liang X, Duesbery NS (2003) Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J Biol Chem 278: 9402–9406.
  66. Kolch W (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351 Pt 2: 289–305.
  67. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239–252.
  68. Roux PP, Blenis J (2004) ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320–344.
  69. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, et al. (2001) MAP kinases. Chem Rev 101: 2449–2476.
  70. Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911–1912.
  71. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37–
    40.
  72. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, et al. (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194–1201.
  73. Ergun S, Kilic N, Wurmbach JH, Ebrahimnejad A, Fernando M, et al. (2001) Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 4: 193–206.
  74. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, et al. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994–1998.
  75. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA (1998) Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 140: 1255–1263.
  76. Ruegg C, Mariotti A (2003) Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell Mol Life Sci 60: 1135–1157.
  77. Kowanetz M, Ferrara N (2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12: 5018–5022.
  78. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, et al. (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84: 1470–1478.
  79. Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851–858.
  80. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, et al. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983–985.
  81. Kim KJ, Li B, Winer J, Armanini M, Gillett N, et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841–844.
  82. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439–442.
  83. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435–439.
  84. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, et al. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62–66.
  85. Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66–70.
  86. Fong GH, Zhang L, Bryce DM, Peng J (1999) Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 126: 3015–3025.
  87. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J (2000) Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 275: 26484–26491.
  88. Milanini J, Vinals F, Pouyssegur J, Pages G (1998) p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 273: 18165–18172.
  89. D'Angelo G, Struman I, Martial J, Weiner RI (1995) Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci U S A 92: 6374–6378.
  90. Rousseau S, Houle F, Landry J, Huot J (1997) p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15: 2169–2177.
  91. Pedram A, Razandi M, Levin ER (1998) Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 273: 26722–26728.
  92. Ennis BW, Fultz KE, Smith KA, Westwick JK, Zhu D, et al. (2005) Inhibition of Tumor Growth, Angiogenesis, and Tumor Cell Proliferation by a Small Molecule Inhibitor of c-Jun N-terminal Kinase. J Pharm Expt Therapeut 313: 325–332.
  93. Shin EY, Kim SY, Kim EG (2001) c-Jun N-terminal kinase is involved in motility of endothelial cell. Expt Mol Med 33: 276–283.
  94. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, et al. (2000) Genes expressed in human tumor endothelium. Science 289: 1197–1202.
  95. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA (2001) Identification of the cellular receptor for anthrax toxin. Nature 414: 225–229.
  96. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, et al. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404–2407.
  97. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099–7109.
  98. Hayashi M, Fearns C, Eliceiri B, Yang Y, Lee JD (2005) Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Cancer Res 65: 7699–7706.
  99. Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, et al. (1997) Endothelial apoptosis in Braf-deficient mice. Nat Genet 16: 293–297.
  100. Mikula M, Schreiber M, Husak Z, Kucerova L, Ruth J, et al. (2001) Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. Embo J 20: 1952–1962.
  101. Huser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, et al. (2001) MEK kinase activity is not necessary for Raf-1 function. Embo J 20: 1940–1951.
  102. Yang J, Boerm M, McCarty M, Bucana C, Fidler IJ, et al. (2000) Mekk3 is essential for early embryonic cardiovascular development. Nat Genet 24: 309–313.
  103. Giroux S, Tremblay M, Bernard D, Cardin-Girard JF, Aubry S, et al. (1999) Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol 9: 369–372.
  104. Ganiatsas S, Kwee L, Fujiwara Y, Perkins A, Ikeda T, et al. (1998) SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Natl Acad Sci U S A 95: 6881–6886.
  105. Yang D, Tournier C, Wysk M, Lu HT, Xu J, et al. (1997) Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc Natl Acad Sci U S A 94: 3004–3009.
  106. Nishina H, Vaz C, Billia P, Nghiem M, Sasaki T, et al. (1999) Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4. Development 126: 505–516.
  107. Wang X, Merritt AJ, Seyfried J, Guo C, Papadakis ES, et al. (2005) Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol Cell Biol 25: 336–345.
  108. Belanger LF, Roy S, Tremblay M, Brott B, Steff AM, et al. (2003) Mek2 is dispensable for mouse growth and development. Mol Cell Biol 23: 4778–4787.
  109. Lu HT, Yang DD, Wysk M, Gatti E, Mellman I, et al. (1999) Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. Embo J 18: 1845–1857.
  110. Tanaka N, Kamanaka M, Enslen H, Dong C, Wysk M, et al. (2002) Differential involvement of p38 mitogen-activated protein kinase kinases MKK3 and MKK6 in T-cell apoptosis. EMBO Rep 3: 785–791.
  111. Pages G, Guerin S, Grall D, Bonino F, Smith A, et al. (1999) Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286: 1374–1377.
  112. Saba-El-Leil MK, Vella FD, Vernay B, Voisin L, Chen L, et al. (2003) An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep 4: 964–968.
  113. Hatano N, Mori Y, Oh-hora M, Kosugi A, Fujikawa T, et al. (2003) Essential role for ERK2 mitogen-activated protein kinase in placental development. Genes Cells 8: 847–856.
  114. Adams RH, Porras A, Alonso G, Jones M, Vintersten K, et al. (2000) Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 6: 109–116.
  115. Mudgett JS, Ding J, Guh-Siesel L, Chartrain NA, Yang L, et al. (2000) Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci U S A 97: 10454–10459.
  116. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, et al. (2000) Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell 102: 221–231.
  117. Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ, et al. (1998) Defective T cell differentiation in the absence of Jnk1. Science 282: 2092–2095.
  118. Yang DD, Conze D, Whitmarsh AJ, Barrett T, Davis RJ, et al. (1998) Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 9: 575–585.
  119. Regan CP, Li W, Boucher DM, Spatz S, Su MS, et al. (2002) Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci U S A 99: 9248–9253.
  120. Sohn SJ, Sarvis BK, Cado D, Winoto A (2002) ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 277: 43344–43351.
  121. Hayashi M, Kim SW, Imanaka-Yoshida K, Yoshida T, Abel ED, et al. (2004) Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest 113: 1138–1148.
  122. Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA (2003) Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 162: 933–943.
  123. Matsumoto T, Turesson I, Book M, Gerwins P, Claesson-Welsh L (2002) p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol 156: 149–160.
  124. Haccard O, Sarcevic B, Lewellyn A, Hartley R, Roy L, et al. (1993) Induction of metaphase arrest in cleaving Xenopus embryos by MAP kinase. Science 262: 1262–1265.
  125. Haccard O, Lewellyn A, Hartley RS, Erikson E, Maller JL (1995) Induction of Xenopus oocyte meiotic maturation by MAP kinase. Dev Biol 168: 677–682.
  126. Gotoh Y, Masuyama N, Suzuki A, Ueno N, Nishida E (1995) Involvement of the MAP kinase cascade in Xenopus mesoderm induction. Embo J 14: 2491–2498.
  127. Corson LB, Yamanaka Y, Lai KM, Rossant J (2003) Spatial and temporal patterns of ERK signaling during mouse embryogenesis. Development 130: 4527–4537.
  128. Curran KL, Grainger RM (2000) Expression of activated MAP kinase in Xenopus laevis embryos: evaluating the roles of FGF and other signaling pathways in early induction and patterning. Dev Biol 228: 41–56.
  129. Gabay L, Seger R, Shilo BZ (1997) In situ activation pattern of Drosophila EGF receptor pathway during development. Science 277: 1103–1106.
  130. Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, et al. (1997) K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 11: 2468–2481.
  131. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, et al. (2006) Germline Mutations in Genes within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome. Science.
  132. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, et al. (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet.
  133. Reynolds JF, Neri G, Herrmann JP, Blumberg B, Coldwell JG, et al. (1986) New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement--the CFC syndrome. Am J Med Genet 25: 413–427.
  134. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, et al. (2004) Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10: 849–857.
  135. Fragale A, Tartaglia M, Wu J, Gelb BD (2004) Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 23: 267–277.
  136. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG (2005) PTPN11 (SHP2) mutations in leopard syndrome have dominant negative, not activating, effects. J Biol Chem.
  137. Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA (2006) HRAS mutations in Costello syndrome: Detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 140: 8–16.
  138. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37: 1038–1040.
  139. Gripp KW (2005) Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 137: 72–77.
  140. Tartaglia M, Gelb BD (2005) Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 6: 45–68.
  141. Merks JH, Caron HN, Hennekam RC (2005) High incidence of malformation syndromes in a series of 1,073 children with cancer. Am J Med Genet A 134: 132–143.
  142. Keren B, Hadchouel A, Saba S, Sznajer Y, Bonneau D, et al. (2004) PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience. J Med Genet 41: e117.
  143. Ward EM, Thun MJ, Hannan LM, Jemal A (2006) Interpreting cancer trends. Ann N Y Acad Sci 1076: 29–53.
  144. Brennan MF, Alektiar KM, Maki RG (2001) Sarcomas of the soft tissue and bone. In: DeVita Jr. V, Hellman S, Rosenberg S, editors. Cancer  Principles & Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins. pp. 1841–1891.
  145. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4–25.
  146. Tomlinson J, Barsky SH, Nelson S, Singer S, Pezeshki B, et al. (1999) Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 5: 3516–3522.